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ABSTRACT 
Purpose: The scientific knowledge of how genes affect disease expression and evolution 
can facilitate more effective environmental and drug therapy interventions delivered by 
health care professionals. The purpose of this paper is to a) describe the role of genetic 
science in healthcare; b) explore genotype determinants for environmental and 
pharmacological interventions; c) and analyze ethical dilemmas, barriers to access, and 
allocation of resources based on genotype.  
Methods:  A review of literature was conducted from the disciplines of nursing, medicine, 
psychology, and sociology using the CINAHL, Ebsco Host, Medline, and PsychINFO 
databases. The search was limited to peer reviewed, full text article in English that dated 
from 1987 to 2011. Inclusion criteria were articles describing environmental, 
pharmacologic, and nutritional influence on genetic expression. Forty-five articles on 
genetic intervention were chosen for further review, in addition to five book publications 
which met inclusion criteria. Many of the sources retrieved were obtained from the 
biomedical sciences and published in the last decade, owing to more recent innovations in 
genetic discovery.  
Results: Disease and treatment must be approached according to genetic profiles for 
effectiveness and to increase health outcomes. Several variations were found regarding 
response to pharmaceuticals, as well as environmental exposures, based on genotype. 
Conclusions: Health care has been practiced using a “universal protocol” approach; 
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however, as the literature reveals, each individual genotype must be taken into account to 
provide optimal care.  
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INTRODUCTION 
The emerging science of human genetics is reshaping the way in which diseases are 
diagnosed, treated, and prevented. Recent advances in the etiology for the genetic 
composition of disease expression and evolution incorporate various relationships 
between genetic health, genetic risk, and intervention. In the past, evidence-based practice 
has focused on the work of Gregor Johann Mendel, which established disease interventions 
based on the expression of single gene locus disorders with simple, genetically attributed 
causes (Frazier, Turner, Schwartz, Chapman, & Boerwinkle, 2004). However, diseases are 
now being studied and treated under the idea of complexity, which involves multi-factorial 
causes. This is because complex diseases, with extreme individual variation, are a public 
health concern and consist of more than just standard vulnerability. As the framework 
implies, there are genetic components with susceptible alleles, that when combined with 
the right triggers, can initiate or exacerbate disease (Frazier et al., 2004). As concluded by 
Mendel’s work, the genotype of an individual is made up of many forms and specific 
variants of a gene that can be responsible for hereditary variation. An individual’s 
phenotype is determined by their genotype. However, genetic disease expression and 
evolution is multi-factorial and can be influenced by the lifestyle an individual pursues, 
including choice of residence, food preferences, occupation, and personal behaviors the 
individual chooses to engage in (D’Amato-Kubiet, 2009).  
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Chronic diseases such as cardiovascular disease, cancer, stroke, and diabetes 
possess a genetic component. However, environmental factors, including lifestyle and 
dietary habits have been known to trigger, accelerate, exacerbate, or prolong onset of 
disease (Greco, Prows, Skirton, Williams, Jones, Middleton, Lewis, Bickford, Daley, Seiler, 
Carson-Smith, 2007). Response to environmental triggers remains inconsistent from one 
individual to another. Genetic variation alone cannot account for disease susceptibility in 
some, without environmental and/or behavioral factors. Although it is well known that 
disease can be controlled by manipulation of lifestyle and environmental factors, chronic 
disease rates are still on the rise. This is because current treatments are based on 
standards of care which establish interventions based on epidemiological studies of large 
populations, not individuals. As stated by Khoury, Davis, Gwinn, Lindegren, and Yoon 
(2005), “our current public health approaches to prevention have not been adequate”. 
Therefore, studies that explore the underlying science of the individual gene-environment 
interactions is expected to unravel more precise interventions to improve quality of life 
(Andreasen & Andersen, 2009). Recently, the genetic basis for drug therapy has been aimed 
at uncovering how variations in multiple genes affect the pharmacokinetics and 
pharmacodynamics of a drug. Genetic variation among individuals has been found to alter 
the therapeutic response to drugs, and can now be linked to adverse reactions or lack of 
response to drug therapy. Understanding genetic variation in response to drugs allows 
medications to be tailored to individual phenotypes and genetic predispositions, rather 
than the use of a universal (standard) protocol that may be less effective or even 
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detrimental to select genotypes. The purpose of this study is to examine barriers and access 
to genetic determinants of disease and their impact on lifestyle based interventions. Two 
areas of genetic discoveries, ecogenetics and pharmacogenetics, will be examined to 
determine their implications for lifestyle interventions and research. The knowledge of 
genetics is rapidly expanding; therefore, there is an increased need to explore the types of 
interventions available for diagnosing, treating, and preventing disease.  
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IMPACT OF GENETIC SCIENCE IN HEALTH CARE 
Human Genome Project 
Several organizations are extensively exploring human genetics in effort to broaden 
our understanding of the role of genetics in the human species, including The Department 
of Energy, The National Institutes of Health, and The Center for Disease Control and 
Prevention. Of these organizations, The Department of Energy established The Human 
Genome Project (HGP), which began in 1990. The results of this project uncovered many 
components in the field of genetic variation. The project’s primary purpose was to 
understand the genetic makeup of the human species in an effort to develop medicines and 
guide decisions in healthcare. The HGP concluded in its results that human beings possess 
approximately 20,500 genes (HGIP, 2010). Further genetic research is being conducted to 
explore genetic expression and will provide insight into disease etiology and pathogenesis. 
Leaders in genetic research propose that disease specific treatments can be developed 
based on finding the multi-factorial genetic/genomic components of disease. The Human 
Genome Project (2010) focused on genetic variants of more common, major diseases such 
as cardiovascular disease, cancer, or diabetes. The results provided the need for greater 
amounts of genetic testing for the underlying gene components of disease (HGIP, 2010).  
Genetic testing involves the analysis of cells for gene products such as proteins, 
enzymes, metabolites, and/or chromosomes (HGPI, 2010). Genetic testing is the precursor 
for genomic health care, which is defined as a highly individualized plan of care that utilizes 
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information related to phenotype responses and gene functions (Shives, 2008). The results 
of these tests allow early identification of disease susceptibility and treatment with 
conventional interventions based on individual genetic variation. Early identification of 
disease involving the application of knowledge about genes is accomplished through the 
use of reproductive and therapeutic genetic testing interventions. Reproductive genetic 
testing interventions are suggested for individuals with a known family history of a genetic 
disorder, to guide reproductive decisions. The testing may be performed on persons who 
intend to have children, or on the fetus if conception has occurred (Buchanan, Brock, 
Daniels, and Wikler, 2000). Therapeutic genetic testing interventions involve tailoring 
environments, nutrition, or medication regimens to optimize health and treatment. In both 
circumstances, genetic screening for high-risk populations or those with family history will 
facilitate early prevention and treatment (Ambler & Brown, 1999). Decisions to pursue 
genetic testing can be determined through the use of genetic counseling. Counseling 
provides an avenue to assist individuals in understanding, adapting to, and using genetic 
information.  Genetic counseling addresses concerns of cost, by assisting individuals in 
utilizing resources, becoming active consumers, and determining the benefits of treatment 
(Greco et al., 2007). 
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ENVIRONMENTAL AND PHARMACOLOGICAL INTERVENTIONS  
Ecogenetics 
The recent movement in molecular science has given significant meaning to the 
principle behind ecogenetics that genes form the basis for disease, but are not expressed 
unless an environmental trigger is exercised (D’Amato-Kubiet, 2009). Ecogenetics uses 
knowledge of how genes work in various environments to predict and intervene on the 
basis of genotype. Exploring ecogenetics provides a basis for understanding how gene-
lifestyle interactions enhance our knowledge of disease, design interventions, and 
eventually facilitate disease prevention (Pomeroy, Soderberg, & Franks, 2009). When 
considering genetic-environmental interactions, it is important to identify the underlying 
susceptibility of genes to biologic and physiologic factors. This will give explanation as to 
why some individuals develop disease when exposed to environmental agents and how 
genetic predisposition may encourage adaptation to environmental exposures (Frazier et 
al., 2004). Additionally, understanding how and which environmental stimuli promote 
manifestation of disease susceptibility genes will lead to individualized disease prevention 
strategies (Frazier et al., 2004).  
Genetic research focused on lifestyle interventions is determining which 
environmental exposures present disease risk and is using genetic sensitivity to chemical 
agents to develop individualized drug therapy plans of care.   It will require an integrative 
approach using epidemiologists’ future studies of environmental causes of human disease, 
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as more genes and biologic pathways are researched (Khoury et al., 2005). Furthermore, 
genetic technology and studies examining large sample groups from defined populations 
have strengthened causal interpretation of genetic knowledge of disease expression 
(Frazier et al., 2004). Environment-gene interactions can be difficult to accurately measure 
or describe because of inconsistent exposure to environmental triggers over time, such as 
changes in residence or dietary habits. However, technological tools for measuring casual 
gene-environment relationships with exposure overtime are rapidly being developed. For 
example, toxicogenomics is being examined to assess the effects of specific chemical 
exposures using gene and protein expression as markers (Khoury et al., 2005).  
Additionally, rather than examining only genetic causes, it will prove most beneficial to 
identify environmental triggers associated with specific genes to better prevent and treat 
disease.     
Insulin Resistance in Metabolic Syndrome 
In a recent study by the American Society for Nutrition, gene-nutrient interactions 
were examined to determine susceptibility to metabolic alterations in metabolic syndrome 
phenotypes, particularly insulin-resistance. The study’s aim was to analyze the degree of 
influence that genetic as well as environmental factors, specifically dietary fat, have on 
health outcomes. The interaction between specific alleles of the adiponectin and plasma 
saturated fatty acids were evaluated to determine responsiveness to dietary intervention.  
Adiponectin plays a major role in regulating insulin sensitivity, and decreased 
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concentrations have been found in metabolic syndrome phenotypes (Ferguson, Phillips, 
Tierney, Perez-Martinez,, Defoort, Helal, Lairon, Planells, Shaw, Lovegrove, Gjelstad, 
Drevon, Blaak, Saris, Golabek, Wilk, Riserus, Karlstrom, Miranda, & Roche, 2010).) The 
study included 451 subjects, all having metabolic syndrome phenotypes. Inclusion criteria 
for metabolic syndrome phenotypes consisted of: body mass index of 20-40kg/m,  and 
required subjects to fulfill ≥ 3 of the following 5 criteria: waist circumference > 102cm 
(men) or 88cm (women), fasting glucose 5.5-7.0mmol/L, triacylglycerol ≥ 1.5mmol/L, 
cholesterol < 1.0mmol/L (men) or 1.3mmol/L (women), and blood pressure ≥ 130/85 mm 
Hg (Ferguson et al., 2010). Genetic analysis tools were then used to identify the presence of 
single-nucleotide polymorphisms in the adiponcentin gene, which contribute to the 
development of insulin resistance in metabolic syndrome (Ferguson et al., 2010). As shown 
in Table 1, the single-nucleotide polymorphisms which showed the greatest interaction 
between saturated-fatty acids and alterations in insulin sensitivity were rs266729 and 
rs10920533. Individuals homozygous for the minor allele in both single-nucleotide 
polymorphisms were found to be more sensitive to an oral fat load and high concentrations 
of saturated-fatty acids. Exploration of similar studies suggests there is a relationship 
between genetic expression of insulin resistance and dietary intake that is unique to 
individuals with diabetes, a component of metabolic syndrome.  Personalized nutrition is a 
modifiable contributor to lifestyle management that can prevent or mitigate disease 
progression since the genotype of these polymorphisms may play a role in the 
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responsiveness to dietary fatty acid modification in subjects with metabolic syndrome 
(Ferguson et al., 2010).     
 Environmental Exposure in Children with Fragile X Syndrome 
According to Murphy & Abbeduto (2005) developmental theorists studied the role 
of genes in behavioral development using transactional analysis as a theoretical 
framework.  This model provides a method for psychosocial analysis, describing patterns of 
childhood development and external influences (Berne, 2001). The theory implies that an 
individual’s behavior and characteristics are established by an interaction between one’s 
genotype and environmental factors. Within the framework of transactional analysis, a 
genetic anomaly is labeled as predisposing an individual to a behavioral phenotype; 
however, the environment determines the extent of expression (Murphy & Abbeduto, 
2005). To understand the magnitude of environmental influence, a transactional analysis of 
behavioral development must be applied to interventions associated with genetic 
anomalies. In the example of fragile X syndrome, an X-linked genetic disorder, language 
development with difficulty in communication skills, hyperarousal and hypersensitivity to 
sensory stimuli are common traits (Murphy & Abbeduto, 2005). Using transactional 
analysis, developmental theorists concluded that these syndrome-specific behaviors are 
extremely variable and may be prompted more by environmental factors such as anxiety 
and arousal than by the severity of the genetic disorder. Therefore, modification of these 
environmental factors may optimize levels of arousal and enhance learning ability (Murphy 
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& Abbeduto, 2005). However, it must not be overlooked that environmental modifications 
used to promote development have the potential to further distinguish the course of the 
disorder. Behavior and lifestyle factors, including modifications of surroundings enhance 
development by decreasing arousability (Murphy & Abbeduto, 2005). But, these same 
modifications may create nonnormative environments, while promoting syndrome-specific 
behaviors. In an effort to correct or avoid hyperarousal or overstimulation, the child may 
become dependent on the use self-directed behaviors or avoidance of social interaction 
(Murphy & Abbeduto, 2005) As a child with fragile X syndrome moves through 
developmental stages, the behavioral phenotype may be become more apparent. 
Inadvertently, environmental modifications in which the child interacts with may promote 
expression, thus decreasing the likelihood of syndrome-specific characteristics diminishing 
over time (Murphy & Abbeduto, 2005). The environmental intervention of transactional 
analysis focuses on transactions that occur between the child and interactions within their 
environment. As shown in Table 1, this approach will assist in identifying 
counterproductive transactions, in addition to communication distortions (Berne, 2001). 
Ultimately, growth promotion and development in a child with fragile X syndrome, depend 
on how the child responds to various environmental input, including responsiveness of 
caregivers to syndrome-specific behaviors.     
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Traveling Population and Thrombosis Formation 
A major area of concern regarding environmental risk factors in genetically 
susceptible individuals is the traveling population. When considering the environmental 
factor of “economy-class syndrome”, there has been concern as to why some individuals 
experience thrombotic events during long duration travel and others do not, given that all 
other environmental factors are equal (Sharma & Gohil, 2010). This gap in knowledge led 
the researchers to examine the influence of genetic factors on the development of venous 
thrombosis. The results found by Sharma & Gohil (2010) identified mutations in the 
coagulation Factor V and Factor II [prothrombin G20210A]. A significantly large portion of 
individuals with single-nucleotide polymorphisms in one of either gene were found to have 
experienced a venous thrombotic event. The study supported its findings through a meta-
analysis review of 173 studies. The results as seen in Table 1, were that a genetic 
contribution could be attributed to at least 200,000 deaths in one year, associated with a 
venous thrombotic event (Sharma & Gohil, 2010). The resultant implications are that 
individuals who are at known genetic risk for developing venous thrombosis, combined 
with the right environmental stimuli [extended flight], may implement preventative 
measures such as using anti-embolism stockings or prophylactic use of selective 
anticoagulants (Sharma & Gohil, 2010).     
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Table 1: Ecogenetic Interventions in Metabolic Syndrome, Children with Fragile X Syndrome, and The 
Traveling Population 
Researcher Population 
Studied 
Genetic 
Alteration 
(SNP) 
Environmental 
Factor 
Findings 
Ferguson et 
al., (2010)  
 
451 subjects, all 
having metabolic 
syndrome 
phenotypes 
 
adiponectin 
gene 
 
[rs266729] 
 
[rs10920533] 
 
saturated fatty 
acids 
 
Alterations in either 
interact with plasma 
saturated-fatty acids 
to alter insulin 
sensitivity. Screening 
for polymorphisms in 
the adiponectin gene 
will help identify those 
that would likely 
benefit from 
modification of dietary 
fat intake. 
 
Murphy & 
Abbeduto 
(2005) 
 
Berne 
(2001) 
 
children of fragile X 
syndrome 
X -chromosome  
 
sensory stimuli 
 
anxiety 
 
 arousal 
 
(transactional 
analysis)  
 
Interventions that 
focus on transactions 
between child & 
environment, in 
response to sensory 
stimulation & socially-
adaptive behaviors 
will decrease the 
extent of expression.  
 
Sharma & 
Gohil 
(2010) 
traveling 
population  
 
 
coagulation 
factor V  
  
factor II 
(prothrombin 
G20210A)  
 
extended flights  
 
Individuals with either 
SNP are at increased 
risk for experiencing a 
venous thrombosis 
event and would 
benefit from 
prophylactic 
anticoagulant therapy 
&/or preventative 
measures (anti-
embolic stockings). 
 
Note: ᵃ Results from Ferguson et al., (2010). Gene-nutrient interactions in the metabolic syndrome: single nucleotide 
polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. American 
Journal of Clinical Nutrition, 91, 794-801.  ᵇ Results from Murphy, M. Abbeduto, L. (2005). Indirect genetic effects and the early 
language development of children with genetic mental retardation syndromes, the role of joint attention. Journal of Special Care 
Practices, 18(1), 47-59. &Berne, E. (2001). Transactional analysis in psychotherapy. London: Souvenir. ᶜ Results from Sharma, 
P., & Gohil, R. (2010). Genetic risk factors for venous thrombosis: the end of the beginning?. Expert Review of Cardiovascular 
Therapy, 8(1), 11-13. doi:10.1586/erc.09.159 
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Pharmacogenetics 
Pharmacogenomics is the study of how genes affect individual drug responses. An 
individual’s genetic makeup can result in alterations in genes that code for metabolizing 
enzymes and drug targets. Through an analysis of an individual’s complete DNA structure, 
the body’s response to medicines can be studied to predict therapeutic and adverse effects 
(HGPI, 2010). Pharmaceutical interventions can be tailored to an individual to produce 
more effective and safe medications when the genetic susceptibility of a drugs 
pharmacokinetics are determined.   The benefits of individualized drug therapy are 
exceptionally profound for the treatment and management of disease conditions. Through 
the analysis of human DNA/RNA molecules, proteins, and enzymes and the genes 
associated with specific diseases, a stronger therapeutic response can be created, with drug 
targets that are disease specific (HGPI, 2010). When beginning an individualized drug 
regimen, genetic results can be analyzed to determine the most effective drug response 
that can be elicited for a specific individual.  Tailoring drugs to an individual’s genetic 
composition can optimize therapeutic response to a drug while minimizing the risks of 
adverse reactions to the agent.  Pharmacogenetics focuses on identifying genotypes that 
drive favorable or unfavorable drug responses (O’Malley, 2011). This can also lead to a 
reduction in the cost of a therapeutic agent by lessening the risk associated with 
prescribing ineffective drugs to certain genotypes. Currently, pharmacodynamics and 
pharmacokinetics are based on anthropometric measurements and age (HGPI, 2010).  
Using one’s genotype provides a more accurate measurement of how the body metabolizes 
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a drug and determines dosage requirements. In fact, the Federal Drug Administration 
(FDA) has issued a warning that states, “drug outcomes are the function of genetic makeup 
and response variance, and side effects and adverse outcomes can be significantly 
controlled by prescribing based on a genetic profile” (O’Malley, 2011). Perhaps the most 
important indication for receiving the correct medication the first dose would be to 
eliminate the 100,000 deaths that occur annually as a result of pharmaceutical-genetic-
mismatch (HGPI, 2010). These deaths resulted from either drug accumulation of toxic 
levels in the blood or the body’s inability to use the drug based on genetic factors. Other 
topics to consider while examining the benefits of pharmacogenetics are the use of new 
medications in clinical trials for drug discovery and development, vaccinations, and the 
reduction of overall health care costs (HGPI, 2010). Genetic profiling allows researchers to 
categorize individuals for clinical trials based on genotype, resulting in shorter clinical 
trials and reduced number of subjects needed (O’Malley, 2011). Furthermore, with the use 
of genetic profiling to identify individual variation in drug response, the time for drug 
development has the potential to reduce from 10 to 12 years to 3 to 5 years (O’Malley, 
2011).    
Ethnopharmacology in Psychotropic Drugs 
According to The Human Genome Project (2010), there are over 30 classes of drugs 
identified which are metabolized by the liver. The rate and amount of metabolism is 
influenced by DNA variations of cytochrome P450 genes. In the example of 
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ethnopharmacology (Shives, 2008), variations in the metabolism of psychotropic drugs are 
found, based on ethnicity. When prescribing psychotropic medications in the treatment of 
psychiatric disorders, differences in ethnic hepatic-biotransformation must be taken into 
consideration. Individuals who possess high enzymatic activity metabolize these 
medications at a very high rate, where as individuals with less or inactive enzymatic 
activity metabolizes the medications much slower (Shives, 2008). Adverse drug events can 
be a direct result of the rate and ability to metabolize medication. Literature reviewed by 
Shives (2008) identified that a large percent of the Eastern Asian population are 
considered “poor metabolizers”. Additionally, the same percentages of African Americans 
have been found to metabolize these drugs at a slower rate, in comparison to Caucasians. 
The resulting effect, shown in Table 2, can lead to an increased incidence of adverse effects 
(Shives, 2008). In consideration of a specific drug, lithium, it has been found that these 
particular ethnic groups also require reduced doses. Variations in plasma protein that 
binds lithium result in accumulation of the drug in the blood. Therefore, a dosage reduction 
is required to reduce the risk of lithium toxicity in the central nervous system (Shives, 
2008).   
Hepatic Metabolism of Anticoagulants 
Hepatic pathways that metabolize anticoagulants are the latest trend in genetic 
testing that combines an individual’s cellular environment with genetic vulnerability to 
drug therapy. The FDA recommends that patients undergo genetic testing for alterations in 
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enzymatic activity prior to prescribing the treatment of the anticoagulant agent, warfarin 
[Coumadin] (Lehne, 2010). When daily anitembolism therapy is necessary, dosage 
adjustments should be considered in individuals with alterations in the cytochrome P450-
2C9 [CYP2C9] and Vitamin K epoxide reductase [VKORC1] (refer to Table 2). Warfarin is 
used in the treatment for long-term prophylaxis of thrombosis formation, including 
prevention of venous thrombosis, prevention of thrombosis during atrial fibrillation, and to 
reduce the risk of recurrent transient ischemia attacks (Lehne, 2010). The enzyme CYP2C9 
is responsible for warfarin metabolism; hence, individuals with alterations in this enzyme 
metabolize the drug at a slower rate. Additionally, VKORC1 is the target enzyme that 
warfarin inhibits, thus genetic alterations increase the enzyme’s sensitivity to warfarin. 
Because warfarin has a narrow therapeutic index, these individuals are at greater risk for 
warfarin-induced bleeding, which concludes that these individuals require a dosage 
reduction (Limdi, Wiener, Goldstein, Acton, & Beasley, 2009).  
In regards to genetic influence on drug responses, several European phenotypes, 
shown in Table 3, demonstrate genetic tendencies to be slow metabolizers of 
succinylcholine, resulting in a need for dosage adjustments (Lehne, 2010). As shown in 
Table 4, approximately 52% of Caucasians are slow metabolizers of the drug isoniazid, 
used in the treatment of tuberculosis (Lehne, 2010). In the treatment of cancer, Table 3 
demonstrates that a small percentage of the United States population have genetic 
alterations in alleles that slow the metabolism of the drug fluorouracil, a chemotherapeutic 
agent used in the treatment of cancer for over 40 years (Lehne, 2010).  In some cases, this 
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reduction in metabolism has resulted in death (Lehne, 2010). Lastly, Asians have been 
found to have alterations in human leukocyte antigens [HLA-B 1502], which increases the 
risk for developing life-threatening skin reactions when using the drug carbamazepine 
[Tegretol] (refer to Table 4). The FDA states that tests are available to identify genetic 
alterations in metabolism and recommends genetic screening prior to initiation of 
treatment (Lehne, 2010).             
Ethnic Variation in Biotransformation of Chemotherapeutic Agents 
Ethnic variations in response to chemotherapeutic drugs in the treatment of 
leukemia have been a focus of genetic susceptibility research.  Displayed in Table 3, some 
Caucasians possess genetic variations of the enzyme thiopurine methyltransferase (HGPI, 
2010). This enzyme is responsible for breaking down chemotherapeutic agents for use in 
the body. Genetic variations result in the inactivation of enzymatic activity that promotes 
the breakdown and excretion of the drug. The inability to metabolize the drug results in 
toxic blood levels of highly chemotaxic agents to remain in the body longer (HGPI, 2010).  
Therefore, screening for the deficiency prior to administering this class of medications is 
essential (HGPI, 2010). 
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Table 2: Pharmacogenetic Interventions in Warfarin Users, and Eastern Asian and African American 
Populations 
Researcher Population Studied Genetic 
Alteration 
Pharmaceutical 
Factor 
Findings 
Shives (2008) 
 
Eastern Asian 
 
cytochrome P450 
 
psychotropic drugs, 
especially lithium 
(used in the 
treatment of 
psychotic disorders 
possess lower 
enzymatic activity in 
the metabolism of 
psychotropic drugs 
and require a 
dosage reduction 
 
Shives (2008)  
 
African American  
 
cytochrome P450  
 
psychotropic drugs, 
especially lithium 
 
(used in the 
treatment of 
psychotic disorders 
possess lower 
enzymatic activity in 
the metabolism of 
psychotropic drugs 
and require a 
dosage reduction 
 
Lehne (2010)  
 
Warfarin Users  
 
cytochrome P450-
2C9 [CYP2C9]  
 
Vitamin K epoxide 
reductase  
 
warfarin 
[Coumadin]  
 
(used in the 
prevention of 
thrombosis)  
 
metabolize this drug 
at slower rates than 
current prescribing 
guidelines follow, 
and require dosage 
adjustments to 
decrease the risk of 
warfarin induced 
bleeding  
 
Note: ᵃᵇ Results from Shives, L.R. (2008). Basic concepts of psychiatric-mental health nursing. Lippincott 
Williams & Wilkins: Philadelphia, PA ᶜ Results from Lehne, R. A. (2010). Pharmacology for nursing care (7th 
ed.). St. Louis: Saunders Elsevier. 
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Table 3: Pharmacogenetic Interventions in Europeans, U.S. Populations, and Caucasians 
Researcher Population 
Studied 
Genetic Alteration Pharmaceutical 
Factor 
Findings 
Lehne (2010) 
 
European (1 in 
3500) 
 
butyrlcholinesterase  
(enzyme) 
 
Succinylcholine 
 
(used in 
neuromuscular 
blockade) 
 
reduced rates of 
the enzyme 
responsible for 
the metabolism 
of this drug, 
requiring a 
dosage reduction 
to prevent 
permanent 
paralysis. 
 
Lehne (2010)  
 
1 % of the U.S. 
population  
 
dihdropyrimidine 
dehydrogenase 
(enzyme)  
 
Fluorouracil  
 
(used in the 
treatment of 
cancer)  
 
produce a poor 
form of this 
enzyme, which is 
responsible for 
metabolism of 
the drug  
 
HGPI (2010)  
 
Caucasian  
 
thiopurine 
methyltransferase  
(enzyme)  
 
chemotherapeutic 
agents  
 
(used in the 
treatment of 
cancer)  
 
results in 
inactivation of 
enzymatic 
activity that 
promotes the 
breakdown and 
excretion of this 
drug, increasing 
the risk for toxic 
blood levels  
 
Note: ᵃᵇ Results from Lehne, R. A. (2010). Pharmacology for nursing care (7th ed.). St. Louis: Saunders 
Elsevier. ᶜ Results from HGPI, Human genome project information. (2010). U.S. Department of Energy 
Genome Program's Biological and Environmental Research Information System (BERIS). 
http://genomics.energy.gov. 
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Table 4: Pharmacogenetic Interventions in Asian and Caucasian Populations  
Researcher Population 
Studied 
Genetic 
Alteration 
Pharmaceutical 
Factor 
Findings 
Lehne (2010) 
 
Asian 
 
human leukocyte 
antigens 
[HLA-B 1502] 
 
carbamazepine 
[Tegretol] 
 
(used in the 
treatment of 
seizures) 
 
produce this 
unusual antigen 
which increases 
the risk for 
developing life-
threatening skin 
reactions when 
using the drug 
 
Lehne (2010)  
 
Caucasian (1 in 14)  
 
cytochrome P450   
 
Morphine  
 
(used in the 
treatment of pain 
are unable to 
convert codeine 
into morphine (its 
active form), 
resulting in no 
pain relief  
 
Lehne (2010)  
 
 
U.S. Caucasian  
 
N- 
acetyltransferase-
2  
(enzyme)  
 
Isoniazid  
 
 (used in the 
treatment of 
tuberculosis) 
 
2 different forms 
of the enzyme:  
52% were found 
to be slow 
metabolizers, 
putting them at 
risk for toxicity;  
48% were found 
to be rapid 
metabolizers, 
putting them at 
risk for treatment 
failure  
 
Note: ᵃᵇᶜ Results from Lehne, R. A. (2010). Pharmacology for nursing care (7th ed.). St. Louis: Saunders 
Elsevier.  
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ECO-PHARMACO-GENETIC INTERVENTIONS 
Hypertension in the African American Population 
Currently, a gap in knowledge exists in the development and treatment of 
hypertension associated with African Americans. The prevalence of hypertension in African 
Americans is nearly twice as much compared to other races (Ambler & Brown, 1999). The 
increasing incidence of hypertension in this population has influenced researchers to 
investigate genetic variations and physiological differences among African Americans. 
Ambler & Brown (1999) concluded that this population possesses unique genetic allele 
expressions that may interact with environmental-behavioral conditions to increase blood 
pressure. These characteristics include an elevated sensitivity of blood pressure to sodium 
transport, with alterations in renal sodium handling (Ambler & Brown, 1999). Exposure to 
environmental risk factors (Table 5), such as sedentary lifestyle, increased sodium and 
caloric intake, and stress further influence these characteristics and associated 
complications.  In the treatment hypertension, Ambler & Brown (1999) examined the 
response of antihypertensive therapy and gene variations in the rennin-angiotensin-
aldosterone system (RAAS). African Americans were found to be better responders to 
diuretic and calcium channel blocker therapies, and less to ACE inhibitors. The authors 
attributed these findings to the mechanism of action the therapies had on the RAAS. This 
study demonstrated a correlation between polymorphisms in the rennin and atrial 
natriuretic peptide genes and hypertension in African Americans (Ambler & Brown, 1999).   
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Further clarifying these findings, an additional study conducted by Frazier et al. (2004) 
examined therapeutic response to antihypertensive therapy in African American women. 
The results concluded that variations in genes in the RAAS of this population were 
responsible for the blood pressure response to diuretic therapy.  
Percutaneous Interventions in Cardiovascular Disease 
Knowledge of environmental stimuli that trigger disease susceptible genes can be 
used in healthcare education to promote disease prevention and maintenance. Genetic 
susceptibility in individuals with cardiovascular disease and comorbidities related to 
complications from cardiac conditions are being explored for their potential to prevent 
disease.  More than 2 million people annually undergo cardiac procedures in the United 
States (O’Malley, 2010). Genetic determinants of disease suggest that certain 
polymorphisms of alleles can predetermine poor physiologic outcomes which increase the 
likelihood of complications and the need for further therapeutic interventions (Frazier et 
al., 2004). Genetic susceptibility for adverse events such as: thromboembolism, restenosis, 
or death, exists in individuals who possess polymorphisms in prothrombin [G20210A] and 
antithrombin III, as seen in Table 5. Prothrombin plays a significant role in hemostasis, 
while antithrombin III keeps the hematologic system under control by inactivating clotting 
factors (Frazier et al., 2004). A genetic disruption in either hematologic cascade can 
potentially increase the risk of complications in individuals with cardiovascular disease 
undergoing treatment.  Therefore, the environmental components, or individual treatment 
 
 
23 
 
options, can be determined based on genetic profiling for susceptibility to drug therapy 
effectiveness.  
Clopidogrel [Plavix] has been the antiplatelet drug of choice in the prevention of 
stenosis of coronary stents (Lehne, 2010). A study conducted by O’Malley (2011) 
determined that patients with alterations in the gene that is responsible for the metabolism 
of Plavix, CYP2C19, are less likely to benefit from this drug therapy and are at increased 
risk thrombotic events. Additionally, the study found that individuals with polymorphisms 
in the enzyme PON1, required in the transformation of Plavix into an active metabolite, 
experienced higher risk of thrombosis formation post-stent placement and use of the drug 
(O’Malley, 2011). Genetic screening for these polymorphisms will lead to more 
individualized planning, resulting in better patient outcomes regarding cardiac procedures 
(Frazier et al., 2004). The monetary cost for invasive cardiac procedures is steep and the 
associated emotional stress of undergoing a cardiac procedure can sometimes worsen the 
condition (Caldwell, Arthur, Natarajan, & Anand, 2007). Identifying individuals susceptible 
to targeted therapies, such as a new drug regimen or diet and lifestyle modifications, can 
help decrease the emotional stress and healthcare cost of invasive procedures and 
expensive drug therapies (Caldwell et al., 2007). 
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Table 5: Eco-Pharmaco-Genetic Interventions in African American populations and Individuals 
Undergoing Invasive Cardiac Procedures 
Research
er 
Population 
Studied 
Genetic Alteration Pharmaceutical 
Factor 
Environment
al Factor 
Findings 
Ambler & 
Brown 
(1999) 
 
Frazier et 
al., (2004) 
 
African 
American 
 
renal sodium 
handling 
 
rennin-angiotensin-
aldosterone system 
(RAAS) 
 
anti-
hypertensive 
drugs 
 
[diuretics, 
calcium channel 
blockers, ACE 
inhibitors] 
 
sedentary 
lifestyle 
 
increased 
sodium intake  
 
increased 
caloric intake  
 
stress 
 
increased 
sensitivity to 
elevated blood 
pressure, especially 
in response to 
favorable 
environmental 
triggers; 
respond better to 
diuretic or calcium 
channel blocker 
therapies & less to 
ACE inhibitors 
 
Frazier et 
al., (2004) 
 
O’Malley 
(2010) 
 
Individuals 
Undergoing 
Cardiac 
Procedures  
 
prothrombin   
(G20210A)  
 
 antithrombin III 
 
CYP2C19 (enzyme) 
 
PON1 (activator 
enzyme) 
 
clopidogrel 
[Plavix]  
 
(used in the 
prevention of 
stenosis post 
stent placement 
cardiac 
procedures 
 
percutaneous  
intervention 
[PCI, stent] 
 
Coronary 
Artery Bypass 
Graft [CABG] 
 
both cause 
increased risk for 
adverse events: 
thromboembolism, 
restenosis, or 
death; determine if 
patient is better 
candidate for PCI or 
CABG 
 
inability to 
metabolism drug or 
convert to its active 
form for use 
 
Note: ᵃ Results from Ambler, S., & Brown, R. (1999). Genetic determinants of blood pressure regulation. Journal of 
Cardiovascular Nursing, 13(4), 59. Retrieved from EBSCOhost. & Frazier, L., Turner S. T., Schwartz, G. L., Chapman, 
A. B., & Boerwinkle, E. (2004). Multilocus effects of the renin angiotensin aldosterone system genes on blood 
pressure response to a diuretic. Pharmacogenomics Nature, 4, 17-23. ᵇ Results from Frazier et al. (2004) Multilocus 
effects of the renin angiotensin aldosterone system genes on blood pressure response to a diuretic. 
Pharmacogenomics Nature, 4, 17-23. & O'Malley, P. (2011). Pharmacogenomics for the clinical nurse specialist---
genetics, prescribing, and outcomes. Clinical Nurse Specialist: The Journal for Advanced Nursing Practice, 25(3), 
110-112. doi:10.1097/NUR.0b013e3182170fc2.  
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BARRIERS AND ETHICAL DILEMMAS TO GENETIC INTERVENTION 
Barriers, Allocation and Access 
Barriers to genetic determinants of lifestyle management regarding ecogenetic and 
pharmacogenetic interventions include disparities in the availability of appropriate 
nutritional or medication resources among different income levels, geographical locations, 
and ethnic differences.  Likewise, barriers in identifying and determining which gene 
variations affect drug response can impact pharmaceutical efficacy. Genetic coding that 
determines individualized drug therapy can potentially reduce the marketable populations 
for pharmaceutical stakeholders and places limitations on drug therapy alternatives 
available to consumers (HGPI, 2010).   
Although genetic research is currently revealing lifestyle modifications and selective 
drug therapy based on genetic variation, increasing concern exists about the accessibility of 
resources. Molecular profiling technology, genetic sequencing and mapping, are currently 
being used to expand genetic profiling and interventions; however, a financial foundation 
for funding has not yet been established. So the questions are: do individuals wait for 
technology to become cheaper? And when and where do we start screening (Sharma & 
Gohil, 2010)? Therefore, as research progresses, there is an increased need for program 
development focused on how and which individuals will obtain genotype-based resources. 
One program in favor of resource accessibility, the Genetic Diseases Act in 1976, brought 
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funding of state and federal programs to genetic services, and continues to represent the 
importance of integrating genetics into health care services (Greco et al., 2007).  
Exploration of future genetic studies that will alter lifestyles and interventions to 
prevent or maintain disease will focus on mitigating questions pertaining to access of 
genetic testing and outcomes.  The new wave of genetics comes with risks of discrimination 
in finances, employment and insurance (O’Malley, 2011). To begin with, the genetic 
community lacks consistency in determining if intervention and testing is made available 
only to individuals who have the financial means.  There is also no clear definition for how 
health insurance programs will be impacted based on genetic profiling, which poses major 
ethical and financial implications to genetic use. Other barriers to enacting genetic lifestyle 
management principles include cultural beliefs, individual access to health care services, 
and genetic screening, as well as employment opportunities and education of health care 
providers in regards to genetic interventions. The moral and ethical duty of individuals to 
the community is also a concern where environmental health issues can influence 
interventions, regardless of personal beliefs. Health care institutions and professionals 
must be prepared to put concepts related to genetic disease management to use for 
consumer health to be initiated (Frazier et al., 2004).  
Cambridge Genetics Knowledge Park 
Currently, The Cambridge Genetics Knowledge Park of the United Kingdom (CGKP) 
is investing substantial time and money to develop programs that will lead to the 
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involvement of the general public with ethical, legal, and societal issues associated with 
advances in human genetics (Dutta, Brice, & Wallace, 2005). The ethical and social issues 
that are brought forth are not necessarily new to the health care industry. Ethical issues 
associated with human genetics may include individual obligation for genetic susceptibility 
testing and to community/family awareness. Societal issues arise from individuals having 
equal access to care and appropriate allocation of resources (Frazier et al., 2004).  In an 
effort to minimize such dilemmas, this organization has included experts in the fields of 
philosophy, law, health economics and social science, epidemiology, molecular biology, and 
clinical and public health medicine in genetic decision making (Dutta et al., 2005). 
Ultimately, collaboration across the domains of ethicists, scientists, philosophers, 
individuals, insurers, and employers will guide genetic use in health care. The CGKP is also 
working with the insurance industry to determine the basis for insurance premiums based 
on genetic screening profiles. GINA, the act passed disabling insurance companies from 
discriminating or raising premiums based on genetic profiles, will protect individuals from 
discrimination based on genetic findings.  Additionally, the CGKP is training specialists to 
further genetics education to the next generation (Dutta et al., 2005). The organization 
researched the current knowledge level of a wide variety of healthcare providers, as well as 
patients, to assess the needs of different groups for education in genetics, and to implement 
effective ways of providing the necessary knowledge and skills based on those findings 
(Dutta et al., 2005).   
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Ethical Principles of Autonomy and Justice 
When considering the principle of autonomy, or self-determination, genetic 
interventions are described as services offered to individuals as goods for private 
consumption, to be accepted or refused as individuals see it (Buchanan et al., 2000). 
Buchanan et al. (2000) argues that this personal service model honors only those who are 
in a position to chose or afford genetic interventions, and not necessarily those affected 
who may be in need. However, with proper allocation of resources and the incorporation of 
laws and insurance policies, all of society may benefit. With new discoveries, a public 
health model will guide genetic interventions.  The interventions will become the norm of 
health care services, which will affect the overall genetic health of society.    
Equal opportunity must be examined when considering the principle of justice in 
the use of genetic intervention. To ensure justice, no individual must be discriminated upon 
by characteristics such as ethnicity, religion, race, or gender. Rather than being excluded 
for these characteristics as with discrimination, individual characteristics will 
guide/individualize interventions. Another valid point stated by Buchanan et al. (2000) is 
Norman Daniel’s theory of just health care. This theory proposes that a “just health care 
system should strive to remove barriers to opportunity that are due to disease” (Buchanan 
et al., 2000). Genetic interventions will be an important means of eliminating barriers to 
opportunity posed by disease.    
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IMPLICATIONS FOR GENETICS IN NURSING PRACTICE 
 Genetics in nursing practice will focus on health issues, genetic conditions, and 
diseases or susceptibilities to diseases caused or influenced by genes in interaction with 
other risk factors that may require nursing care (Greco et al., 2007). The International 
Society for Nurses in Genetics (ISONG) of the American Nurses Association, established in 
1988, is responsible for defining and developing the scope of professional nursing practice 
in genetics for nurses globally (Greco et al., 2007). ISONG’s vision of “caring for people’s 
genetic health” has been the foundation for defining knowledge and the scope of genetics 
nursing practice. Credentialing for the practice of genetics in nursing care is available 
through the Genetic Nursing Credentialing Commission. Although genetic nursing may 
occur in any health care setting, credentialing is currently reserved for nurses who spend 
at least 50% of their time providing genetic-related nursing care (Greco et al., 2007). The 
delivery of care will be based on the nursing care model, with the incorporation of genetics 
into assessment, diagnosis, planning, implementation, and evaluation. As with other 
practices in the discipline, genetic nursing practice will consist of basic and advanced level 
care degrees.   The future of basic genetic knowledge in nursing will provide a role in the 
delivery of genetic services to all licensed registered nurses, as society becomes more 
aware of the influence of genetics regarding health and disease (Greco et al., 2007). 
 Responsibilities in nursing practice will use genetic information in health 
promotion and teaching, coordination of care, resource referral, consultation, advocating, 
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and counseling. Nurses will assist individuals in becoming informed consumers of the 
established plan care, as well as identifying and evaluating cost-to-benefit factors, safety, 
and availability of interventions (Greco et al., 2007).  The challenge for nursing in 
personalized health care lies in the increasing complexity of healthcare associated with the 
expansion of genetic knowledge (Greco et al., 2007). Nurses must be prepared to 
incorporate individual genotype into the delivery of care. Strategies to overcome this 
challenge focus on an interdisciplinary approach, which is reliant on the overlapping skills 
and knowledge of other disciplines in the implementation of care (Greco et al., 2007). The 
National Coalition for Health Professionals in Genetics has defined core competencies that 
provide a framework for educational programs in nursing. These competencies address the 
biological, ethical, and psychosocial impact of genetics in nursing practice (Greco et al., 
2007). To be prepared for the challenges of genetics, nurses must participate in addressing 
ethical issues and applying genetic research to practice, in collaboration with other team 
members. Nurses will need to stay current with information to provide families and 
patients education about disease process and treatment, while incorporating knowledge of 
the interaction of genetic and environmental factors in disease progression (Frazier et al., 
2004). Lastly, as advances in human genetics expand rapidly, practicing nurses must 
continue to increase technological and educational competencies in the delivery of nursing 
care (Greco et al., 2007).              
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CONCLUSIONS 
Results from this literature review have revealed individualized interventions based 
on genetic profiles. The Human Genome Project (2010) has been the most recent 
foundation for discovery of genetic components, and has provided a basis for current and 
future research in the molecular science field.  Genetic testing poses many challenges to 
society, and therefore should rely on genetic counseling to determine its appropriateness. 
Therapeutic interventions have been discussed, based on ecogenetics and 
pharmacogenetics. Understanding the etiology of disease from a multifactorial standpoint 
will open the door to the next generation of therapeutic interventions (Ambler & Brown, 
1999). In example, when considering genetic vulnerability and environmental factors in 
metabolic syndrome phenotypes, screening individuals for polymorphisms in the 
adiponectin gene will help identify those that would likely benefit from modification of 
dietary fat intake.  Understanding metabolic related polymorphism and its interaction with 
dietary fatty acids assists in identifying causes of insulin-resistance in individuals with this 
genotype. For children with fragile X syndrome, environmental factors that decrease 
sensory stimulation while still promoting socially-adaptive behaviors will decrease the 
extent of expression. Identifying children at early stages in the disease to intervene with 
appropriate environments will halt the progression. Genetic vulnerability in cardiovascular 
disease must be considered when implementing treatment options and establishing plan of 
care. Individuals must be screened for polymorphisms in the prothrombin and 
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antithrombin III nucleotides prior to percutaneous interventions or coronary artery bypass 
to determine the safest treatment option. These polymorphisms are not only specific to 
cardiovascular disease treatment procedures. Individuals, such as the traveling population, 
with these genetic alterations may encounter favorable environmental triggers, extended 
flights, which also increase their risk for experiencing a thromboembolic event.   
With the use of pharmacogenetics, health care models will be developed to create 
more effective drug therapy regimens, while decreasing the risk of adverse events. 
Uncovering genetic variance has demonstrated the differences in ethnic variations, as well 
as single nucleotide polymorphisms that can affect human response to drug therapy. 
Identification of single nucleotide polymorphisms provides a framework to understand 
genetic variation in drug response to create targeted individualized drug therapy (Ambler 
& Brown, 1999). Variations in the hepatic metabolism and the renal system illustrate that 
African Americans are less likely to respond to specific treatments based on genetic 
influence, and would benefit through selective classes of drug therapy. Ethnic variations in 
hepatic metabolism were also analyzed in the East Asian populations and concluded that 
these individuals would benefit from dosage reductions in psychotropic drugs. With the 
number of adverse events and decreased response to drug therapy occurring from 
improper identification to genetic profiling, pharmacogenetics must be implemented to 
improve health outcomes.    
Future studies will need to establish guidelines, roles, and career opportunities for 
health care professionals that incorporate the new evidence pertaining to genetic 
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discoveries and health outcomes into practice. There is also a need to continue research in 
environmental triggers associated with expression of susceptibility genes, as well as how 
genes interact with other genes to promote disease. Genes encode instructions on how to 
make proteins; therefore, proteomics, or studies that explore protein structure and activity 
will need to be focused on in future research.  Millions of alterations in single nucleotides, 
single nucleotide polymorphisms, must be identified to determine their involvement in 
drug response (HGPI, 2010). Universal [standardized] protocols will be replaced with 
treatment options based on genetic profiles. Lastly, an in-depth analysis of ethical-decision 
making must be researched pertaining to the use of genetic interventions for treatment 
versus enhancement. With further research, it can be predicted that genetics will assist in 
closing the therapeutic gap between disease and treatment.    
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